Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Coronavirus COVID-19 BioPharmaceutical Vaccines

Coronavirus Update: Sinovac Latest To Report Vaccine Success In Humans

Plus News From AZ, Sanofi, Lilly, Junshi And Merck & Co.

Executive Summary

Sinovac's candidate is a more conventional inactivated vaccine, but is keeping pace with more modern approaches taken by Moderna and CanSino.

You may also be interested in...



Coronavirus Update: Lilly Initiates 2,400-Patient Nursing Home Trial

Dozens of specially outfitted RVs will roll out to long-term care facilities in the US to test the prophylactic and symptom-reducing potential of the antibody Lilly is developing with AbCellera.

Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection

Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.

Coronavirus Update: How Should Remdesivir Be Priced? ICER Are In Two Minds

Independent drug cost watchdog updates its twin pricing estimates for Gilead's drug - but dexamethasone could tip the balance again.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Coronavirus COVID-19 BioPharmaceutical Vaccines
Latest Headlines

Takeda, Astellas Found New JV To Support Japanese Bioventures

Ipsen Expands Its Rare Neurological Disease Pipeline With Skyhawk Deal

Deal Watch: Six Small Biopharma Mergers Reflect Recent Trend

BMS Fast Tracks CAR-T Manufacturing With Cellares Deal

See All
UsernamePublicRestriction

Register

SC142403

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By